通过测量细菌清除率来量化 秀丽隐杆线虫 的食物摄入量
2024年2月23日
3.2K 次观看
该方案描述了一种基于测量液体培养物中细菌清除率来量化 秀丽隐杆线 虫摄食率的测定法。
我的研究重点是了解药物诱导的摄食行为变化背后的转录和代谢途径。我正在努力寻找降低食物摄入量和延长寿命的药物，表明激活健康的禁食途径。使用我们的细菌清除测定，我们确定了调节血清素诱导的食物摄入和抗精神病药诱导的食物摄入的两种不同途径。
我现在正在研究这些途径与长寿突变体的摄食有何关系。该协议允许研究人员研究喂养与长寿之间的关系。喂养速率通常以咽部泵送为特征。
然而，秀丽隐杆线虫的泵送速率不一定与吃的食物量成正比。当添加到以前的分析中时，该方案给出了每个蠕虫种群的可量化食物摄入量。我们的分析使我们能够使用小分子定量调节摄食，并确定诱导的变化如何同时改变寿命。
概述
该协议描述了一种通过测量液体培养物中细菌的清除来量化秀丽隐杆蚯蚓进食率的检测方法。它允许研究人员探索进食行为与长寿之间的关系。
关键研究组成部分
科学领域
- 神经科学
- 行为生物学
- 代谢研究
背景
- 理解秀丽隐杆蚯蚓的进食行为可以提供代谢途径的见解。
- 之前的检测已经显示咽泵率与食物摄入没有直接关联。
- 该协议增强了对每个蠕虫种群食物摄入的量化。
- 它对于研究药物对进食和寿命的影响至关重要。
研究目的
- 识别可以降低食物摄入并延长寿命的药物。
- 调查响应血清素和抗精神病药物的进食模块化途径。
- 建立一种可靠的方法来量化秀丽隐杆蚯蚓的进食行为。
使用的方法
- 准备用于进食检测的OP50细菌培养物。
- 从NGM培养板上分离并清洗秀丽隐杆蚯蚓幼虫。
- 孵化蠕虫以在药物处理之前达到L4阶段。
- 测量光密度以评估食物摄入的变化。
主要结果
- 识别了影响血清素诱导的进食行为的不同途径。
- 证明daf-16 mu86突变体表现出改变的进食反应。
- 显示在各种药物处理下食物摄入有显著差异。
- 建立了秀丽隐杆蚯蚓进食率与寿命之间的相关性。
结论
- 该检测为研究药物对进食行为的影响提供了宝贵的工具。
- 理解这些途径可能会导致对长寿和代谢健康的见解。
- 该协议可以适应各种实验条件以探索进食动态。
常见问题
这项研究的主要焦点是什么？
该研究的重点是量化秀丽隐杆蚯蚓的进食率及其与长寿的关系。
该检测如何测量进食率？
该检测通过测量液体培养物中细菌的清除来量化食物摄入。
这项研究的意义是什么？
该研究可能提供影响进食行为和寿命的代谢途径的见解。
这个协议可以用不同的药物吗？
是的，该协议可以适应测试各种影响进食行为的药物。
daf-16 mu86突变体的意义是什么？
daf-16 mu86突变体显示改变的进食反应，突出了遗传对进食行为的影响。
如何验证检测的结果？
通过光密度测量和在不同条件下进食率的比较来验证结果。
Executive Industry Relevance
Quantitative measurement of food intake in Caenorhabditis elegans using bacterial clearance enables high-throughput interrogation of metabolic and longevity pathways. This assay supports predictive confidence in early-stage target validation and mechanistic de-risking for compounds modulating feeding behavior. Its scalability and direct quantification facilitate robust portfolio triage in metabolic and aging research pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables direct quantification of food intake to interrogate metabolic pathway hypotheses.
- Supports functional validation of genetic and pharmacological targets affecting feeding and lifespan.
- Facilitates mechanistic de-risking by distinguishing pathway-specific effects on feeding behavior.
- Provides predictive confidence for advancing compounds with metabolic or aging indications.
Screening & Assay Development
- Delivers standardized, quantitative outputs suitable for high-throughput drug screening.
- Enables reproducible assessment of compound effects on feeding across multiple genetic backgrounds.
- Supports assay scalability and platform reuse for diverse compound libraries.
- Prepares validated biological systems for downstream phenotypic screening workflows.
Translational & Preclinical Research
- Aligns feeding phenotypes with translational biomarkers relevant to metabolic health and longevity.
- Provides continuity from early discovery through preclinical validation of metabolic modulators.
- Enables risk-adjusted advancement decisions based on quantitative, disease-relevant endpoints.
- Supports predictive de-risking for compounds targeting conserved metabolic pathways.
Pipeline & Workflow Integration
This bacterial clearance assay integrates from early discovery through lead identification and preclinical research, supporting hypothesis testing and quantitative phenotyping in metabolic and aging pipelines.
- Discovery Biology: Quantifies food intake to clarify pathway involvement and validate target engagement.
- Screening: Provides reproducible, scalable assay outputs for compound evaluation and dose-response analysis.
- Analytics: Generates quantitative readouts (e.g., OD600) enabling statistical comparison of feeding rates across conditions.
- Translational Research: Links feeding modulation to lifespan and metabolic health, supporting biomarker alignment.
- Enterprise Reuse: Offers a reusable, standardized platform for metabolic and longevity research across programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in metabolic target validation.
- Operational Value: Enhances assay standardization, reproducibility, and throughput for screening campaigns.
- Strategic Value: Improves go/no-go decision-making and capital efficiency by providing robust quantitative endpoints.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement of metabolic and aging-related assets.
Implementation Considerations
- Requires expertise in C. elegans handling and quantitative phenotyping.
- Needs access to microtiter plate readers and sterile culture infrastructure.
- Demands cross-team standardization of assay setup and data analysis protocols.
- Adaptable to various genetic backgrounds and compound classes with appropriate controls.
- Dependent on accurate worm counting and bacterial quantification for reliable outputs.
Biopharma FAQs
Why does null hypothesis testing matter for bacterial clearance quantification?
Null hypothesis testing ensures that observed changes in food intake are statistically significant, supporting robust target validation and reducing false positives in metabolic pathway studies.
How does independent variable isolation fit the drug screening workflow?
Isolating variables such as drug concentration or genetic background allows precise attribution of feeding changes to specific interventions, streamlining discovery-stage screening and mechanistic de-risking.
What do quantitative OD600 measurements enable in feeding assays?
Quantitative OD600 measurements provide objective, scalable readouts of bacterial clearance, enabling direct comparison of compound effects and supporting high-throughput screening decisions.
Why are replication requirements critical for cross-functional collaboration?
Replication ensures assay reproducibility and data reliability, facilitating cross-team data sharing and alignment on compound advancement in multi-disciplinary R&D environments.
What statistical analysis capabilities are required before implementation?
Robust statistical analysis, including variance assessment and significance testing, is essential to validate feeding rate differences and inform go/no-go decisions in the discovery pipeline.
